By searching for gene deletion patterns in cancer through a concept the investigators call «synthetic
essentiality,» the team identified a synthetic essential gene known as chromatin helicase DNA - binding factor (CHD1) as a therapeutic
target for prostate and breast cancers lacking a tumor suppressor gene called phosphatase and tensin homolog (PTEN).